MedTrace Logo

A Survey of Physician and Molecular Tumor Board Perspectives on the Clinical Utility and Usability of Cellworks Singula™ and Ventura™ Reports in Facilitating Patient Treatment Decisions for Pan-Cancer Patients

NCT05308784 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 730

Last updated 2023-07-19

No results posted yet for this study

Summary

The purpose of this study is to determine the benefit of Cellworks Singula™ and Ventura™ reports on physician and molecular tumor board treatment recommendations across a large set of pan-cancer indications. Cellworks reports aim to provide NGS-based therapy recommendations to aid the decision-making of patients, physicians, and molecular tumor boards.

Conditions

  • Pan-cancer

Interventions

OTHER

Cellworks Singula and Ventura reports

Personalized drug match reports based on patients' genomic aberration.

Sponsors & Collaborators

  • Cellworks Group Inc.

    collaborator INDUSTRY

  • Avera McKennan Hospital & University Health Center

    lead OTHER

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-01-01
Primary Completion
2025-12-31
Completion
2025-12-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05308784 on ClinicalTrials.gov